CN100441221C - 胸腺素α1在制备减少癌症患者化疗副作用的药剂联合中的应用 - Google Patents

胸腺素α1在制备减少癌症患者化疗副作用的药剂联合中的应用 Download PDF

Info

Publication number
CN100441221C
CN100441221C CNB018089070A CN01808907A CN100441221C CN 100441221 C CN100441221 C CN 100441221C CN B018089070 A CNB018089070 A CN B018089070A CN 01808907 A CN01808907 A CN 01808907A CN 100441221 C CN100441221 C CN 100441221C
Authority
CN
China
Prior art keywords
hydrochloride
injection
acetate
chemotherapy
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018089070A
Other languages
English (en)
Chinese (zh)
Other versions
CN1529614A (zh
Inventor
艾尔费雷德·R·鲁道夫
文森特·中英·谭
玛吉·洁·全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saisheng Pharmaceutical Co ltd
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN1529614A publication Critical patent/CN1529614A/zh
Application granted granted Critical
Publication of CN100441221C publication Critical patent/CN100441221C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB018089070A 2000-05-01 2001-04-19 胸腺素α1在制备减少癌症患者化疗副作用的药剂联合中的应用 Expired - Lifetime CN100441221C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,917 US6462017B1 (en) 2000-05-01 2000-05-01 Method of reducing side effects of chemotherapy in cancer patients
US09/561,917 2000-05-01

Publications (2)

Publication Number Publication Date
CN1529614A CN1529614A (zh) 2004-09-15
CN100441221C true CN100441221C (zh) 2008-12-10

Family

ID=24244042

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018089070A Expired - Lifetime CN100441221C (zh) 2000-05-01 2001-04-19 胸腺素α1在制备减少癌症患者化疗副作用的药剂联合中的应用

Country Status (9)

Country Link
US (1) US6462017B1 (https=)
EP (1) EP1357935B1 (https=)
JP (1) JP2004501870A (https=)
CN (1) CN100441221C (https=)
AT (1) ATE348630T1 (https=)
AU (2) AU5547501A (https=)
CA (1) CA2407238C (https=)
DE (1) DE60125417D1 (https=)
WO (1) WO2001082949A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
JP5044150B2 (ja) * 2005-08-05 2012-10-10 Ｔｏｔｏ株式会社 光照射により薬効を消失させる医薬二酸化チタン複合材
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
WO2009111648A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
ES2876437T3 (es) * 2015-10-29 2021-11-12 Cls Therapeutics Ltd Uso de una ADNasa para mejorar la seguridad y la eficacia de una quimioterapia anticáncer
CN107137684A (zh) * 2017-05-23 2017-09-08 山西中医学院 一种用于胃肠疾病的药物组合物及其制备方法和用途
FR3074042A1 (fr) 2017-11-29 2019-05-31 Galderma Research & Development Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN109820859A (zh) * 2019-04-09 2019-05-31 上海市计划生育科学研究所 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用
IT202300020361A1 (it) 2023-10-03 2025-04-03 Blue Hydrogen Science S R L Nuovi utilizzi di soluzioni acquose ad elevata concentrazione di idrogeno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527393A (en) * 1894-10-09 Busy-test for multiple switchboards
US5273963A (en) 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Also Published As

Publication number Publication date
HK1060280A1 (en) 2004-08-06
WO2001082949A3 (en) 2003-08-28
EP1357935A2 (en) 2003-11-05
DE60125417D1 (de) 2007-02-01
AU2001255475B2 (en) 2006-01-05
EP1357935B1 (en) 2006-12-20
JP2004501870A (ja) 2004-01-22
AU5547501A (en) 2001-11-12
CA2407238C (en) 2012-03-13
WO2001082949A9 (en) 2004-04-22
CA2407238A1 (en) 2001-11-08
WO2001082949A2 (en) 2001-11-08
ATE348630T1 (de) 2007-01-15
CN1529614A (zh) 2004-09-15
US6462017B1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
CN100441221C (zh) 胸腺素α1在制备减少癌症患者化疗副作用的药剂联合中的应用
CA1275922C (en) Treatment of cancer
KR102265952B1 (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP2002537333A (ja) 相乗作用性抗腫瘍組成物
BG65417B1 (bg) Приложение на еритропоетин или еритропоетинови производни за лечение на мозъчни исхемии
MXPA01010138A (es) Docetaxel en combinacion con rhumas her2 para el tratamiento de canceres.
Rosso et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy
KR20050038578A (ko) 항종양성 화합물의 암치료에 있어서의 향상된 용도
Caponigro et al. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
US7070778B2 (en) Therapeutical combination against cancer
EP2254570B1 (en) Combination comprising paclitaxel for treating ovarian cancer
WO2023016519A1 (zh) 和厚朴酚在制备用于治疗脑膜瘤的药物中的用途
EP0488718B1 (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
WO2009075813A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
MX2013008798A (es) Composiciones que comprenden macitentan para el tratamiento del glioblastoma multiforme.
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
HU216826B (hu) Eljárás daganatok kezelésére alkalmazható, kreatin-foszfátot vagy sóját tartalmazó gyógyászati készítmények előállítására
KR20180052761A (ko) T-dm1 불응성 암 환자의 syd985 치료
PL200840B1 (pl) Kompozycje, kompozycja farmaceutyczna, sposób wytwarzania kompozycji oraz zastosowania kompozycji i zastosowania polipeptydu
Ueoka et al. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study
WO2008109349A1 (en) Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
IL317954A (en) Treatment of hematological malignancies with galectin-9 inhibitory antibodies
US20210315898A1 (en) Combination therapy for treating cancer
JPS6338329B2 (https=)
JP2002537334A (ja) 相乗作用性抗腫瘍組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SAISHENG PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: SCICLONE PHARMACEUTICALS INC.

CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: SCICLONE PHARMACEUTICALS, Inc.

Address before: California, USA

Patentee before: SCICLONE PHARMACEUTICALS, Inc.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Application of thymosin alpha 1 in the preparation of pharmaceutical combinations to reduce side effects of chemotherapy in cancer patients

Effective date of registration: 20180629

Granted publication date: 20081210

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: SciClone Pharmaceuticals, Inc.

Registration number: 2018990000506

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Saisheng Pharmaceutical Co.,Ltd.

Address before: California, USA

Patentee before: SciClone Pharmaceuticals, Inc.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: SCICLONE PHARMACEUTICALS, Inc.

Address before: California, USA

Patentee before: Saisheng Pharmaceutical Co.,Ltd.

PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20200925

Granted publication date: 20081210

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: SCICLONE PHARMACEUTICALS, Inc.

Registration number: 2018990000506

PC01 Cancellation of the registration of the contract for pledge of patent right
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20201123

Address after: Greater Cayman, Cayman Islands

Patentee after: Saisheng Pharmaceutical Co.,Ltd.

Address before: California, USA

Patentee before: SCICLONE PHARMACEUTICALS, Inc.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Application of thymosin a1in the preparation of drug combination to reduce the side effects of chemotherapy in cancer patients

Effective date of registration: 20210119

Granted publication date: 20081210

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: Saisheng Pharmaceutical Co.,Ltd.

Registration number: Y2021990000078

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20081210

PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20081210

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: Saisheng Pharmaceutical Co.,Ltd.

Registration number: Y2021990000078

PC01 Cancellation of the registration of the contract for pledge of patent right